The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 28.10.2026. Verfasst von Yanaika S Hok-A-Hin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, North H…. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Alzheimer Disease. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Alzheimer Nederland, Stichting Steun Alzheimercentrum Amsterdam, Health∼Holland.
Abstract (Originalsprache)
INTRODUCTION Novel tools for absolute quantification of established and emerging fluid neuro‐biomarkers are required to advance diagnostic studies and improve biological insights. METHODS We conducted an extensive analytical and clinical validation of the Olink™ Target 48 Neurodegeneration panel (T48 Neuropanel) in 352 paired cerebrospinal fluid (CSF) and plasma samples from cognitively unimpaired controls (CU), Alzheimer's dementia (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), n = 44 per group. Comparisons with benchmark assays were performed. RESULTS Good detectability (CSF: 31 out of 42 assays; plasma: 38 out of 42 assays) and technical performance was observed. Benchmark assays showed good correlations, supporting transformation formula's. Next to emerging biomarkers (MMP10, ITGB2), discriminative performance was excellent in AD: CSF pTau217: area under the curve (AUC) = 1; FTD: plasma neurofilament light chain (NfL): AUC = 0.952; and DLB: CSF dopa decarboxylase (DDC): AUC = 0.901. DISCUSSION This analytical and clinical validation of the T48 Neuropanel highlights initial cutoffs and emerging biomarkers to aid clinical studies for the diagnosis, prognosis, and monitoring of neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, North Holland, The Netherlands.
- Barcelonaßeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Catalonia, Spain.
- Hospital del Mar Research Institute, Barcelona, Catalonia, Spain.
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, North Holland, The Netherlands.
Förderung
- Stichting Alzheimer Nederland
- Stichting Steun Alzheimercentrum Amsterdam
- Health∼Holland
- Ramon y Cajal fellowship
- CaixaResearch Institute
- European Commission (Marie Curie International Training Network
- European Union's Horizon Europe Research and Innovation Programme
- Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discov…
Zitieren
APA
Hok-A-Hin, Y. S., Vermunt, L., de Jong, N., Del Campo Milan, M., Vijverberg, E., Lemstra, A. W., Pijnenburg, Y., van Harten, A. C., & Teunissen, C. E. (2026). The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71866
Vancouver
Hok-A-Hin YS, Vermunt L, de Jong N, Del Campo Milan M, Vijverberg E, Lemstra AW, et al. The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71866
BibTeX
@article{HokAHin2026,
author = {Hok-A-Hin, Yanaika S and Vermunt, Lisa and de Jong, Natascha and Del Campo Milan, Marta and Vijverberg, Everard and Lemstra, Afina W and Pijnenburg, Yolande and van Harten, Argonde C and Teunissen, Charlotte E},
title = {The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71866}
}
EUVIMED